CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Shares withheld for taxes CFO and Treasurer gave up 1,954 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Executive or director change
- 8-K/A Event Shareholder vote results
- 4 Open-market sale 10% owner sold 1,443,247 shares at $31.65 ($45,678,768)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
- 4 Open-market sale 10% owner sold 250,000 shares at an average $23.97 ($5,993,052)
- 4 Open-market sale 10% owner sold 255,000 shares at an average $24.72 ($6,304,373)
- 4 Gift President and CEO gave 40,000 shares (gift)
- 4 Open-market sale Director sold 400,000 shares at $26.10 ($10,440,000)
- 4 Open-market sale 10% owner sold 1,922,855 shares at $25.75 ($49,513,516)
- 8-K Event Shareholder vote results
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 28 of 40 · 789 filings